Neumega, Interleukin 11 (oprelvekin) dosing, indications, interactions, adverse effects, and more

Sections

Sections oprelvekin
Dosing & Uses
Adverse Effects
Warnings
Pregnancy
Pharmacology
Images
Patient Handout
Formulary

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

powder for injection

5mg/vial

Prevention of Thrombocytopenia

50 mcg/kg SC qDay for 10-21 days

Renal Impairment

CrCl <30 mL/min: 25 mcg/kg SC qDay for 10-21 days (postnadir platelet count > 50,000/cu.mm

Administration

Initiate 6-24 hours after completion of chemotherapy, discontinue >2 days before next chemotherapy session

Continue dose until Plt >50,000/cu.mm

Reconstitute vial with 1 mL sterile water for injection (without preservative, supplied) to obtain a 5 mg/mL solution, dissolve by gentle swirling

Use within 3 hours of reconstitution (reconstituted solution may be refrigerated but do NOT freeze)

Safety & efficacy not established

>10%

Nausea/vomiting (77%)

Edema (59%)

Neutropenic fever (48%)

Dyspnea (48%)

Mucositis (43%)

Diarrhea (43%)

Rhinitis (42%)

Headache (41%)

Dizziness (38%)

Fever (36%)

Insomnia (33%)

Cough (29%)

Rash (25%)

Pharyngitis (25%)

Tachycardia (20%)

Vasodilatation (19%)

Palpitations (14%)

Syncope (13%)

Atrial fibrillation (12%)

1-10%

Pleural effusions (10%)

Papilledema (2%)

Anti-oprelvekin antibody formation (1%)

Contraindications

Hypersensitivity

Cautions

Discontinue permanently if anaphylactic reaction

Atrial arrhythmias, CHF, aggressively hydrated patients, history of stroke/TIA, papilledema (risk of blindness)

Risk of severe but reversible fluid retention

Risk of papilledema, especially in children

Anemia appears 3 days after initiating treatment & resolves about 2 wk after discontinuation

Dosing for longer than 21 days not recommended

Pregnancy & Lactation

Pregnancy Category: C

Lactation: Not known if excreted in breast milk; not recommended

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

Recombinant Interleukin-11, thrombopoietic growth factor; stimulates thrombopoiesis & maturation, which results in proliferation of megakaryocyte progenitors and subsequently increases platelet production

Pharmacokinetics

Bioavailability: 80%

Excretion: Urine (primarily)

Half-Life: 5-9 hr

Peak plasma time: 1-6 hr

Images

No images available for this drug.

Patient Handout

A Patient Handout is not currently available for this monograph.

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Create Your List of Plans

Adding plans allows you to:

View the formulary and any restrictions for each plan.
Manage and view all your plans together – even plans in different states.
Compare formulary status to other drugs in the same class.
Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

View explanations for tiers and restrictions

Tier	Description
1	This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2	This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC	NOT COVERED – Drugs that are not covered by the plan.

Code	Definition
PA	Prior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL	Quantity Limits Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST	Step Therapy Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR	Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]